Implementation of esophageal endoscopic submucosal dissection in Spain: Results from the nationwide registry.
Implementación de la disección endoscópica submucosa esofágica en España: resultados del registro nacional.
Adverse events
Barrett esophagus
Cáncer de esófago
Disección endoscópica submucosa
Endoscopia
Endoscopic submucosal dissection
Endoscopy
Esophageal neoplasms
Esófago de Barrett
Eventos adversos
Journal
Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671
Informations de publication
Date de publication:
02 Mar 2023
02 Mar 2023
Historique:
received:
21
10
2022
revised:
24
01
2023
accepted:
21
02
2023
pubmed:
5
3
2023
medline:
5
3
2023
entrez:
4
3
2023
Statut:
aheadofprint
Résumé
The outcomes of endoscopic submucosal dissection (ESD) in the esophagus have not been assessed in our country. Our primary aim was to analyze the effectiveness and safety of the technique. Analysis of the prospectively maintained national registry of ESD. We included all superficial esophageal lesions removed by ESD in 17 hospitals (20 endoscopists) between January 2016 and December 2021. Subepithelial lesions were excluded. The primary outcome was curative resection. We conducted a survival analysis and used logistic regression analysis to assess predictors of non-curative resection. A total of 102 ESD were performed on 96 patients. The technical success rate was 100% and the percentage of en-bloc resection was 98%. The percentage of R0 and curative resection was 77.5% (n=79; 95%CI: 68%-84%) and 63.7% (n=65; 95%CI: 54%-72%), respectively. The most frequent histology was Barrett-related neoplasia (n=55 [53.9%]). The main reason for non-curative resection was deep submucosal invasion (n=25). The centers with a lower volume of ESD obtained worse results in terms of curative resection. The rate of perforation, delayed bleeding and post-procedural stenosis were 5%, 5% and 15.7%, respectively. No patient died or required surgery due to an adverse effect. After a median follow-up of 14months, 20patients (20.8%) underwent surgery and/or chemoradiotherapy, and 9 patients died (mortality 9.4%). In Spain, esophageal ESD is curative in approximately two out of three patients, with an acceptable risk of adverse events.
Identifiants
pubmed: 36870477
pii: S0210-5705(23)00042-0
doi: 10.1016/j.gastrohep.2023.02.008
pii:
doi:
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Elsevier España, S.L.U. All rights reserved.